Trial Profile

A real-world observational, prospective, 12-month study assessing impact of golimumab on quality of life and other patient-reported outcomes in patients with rheumatoid arthritis

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Apr 2022 Primary endpoint (The impact of golimumab on QoL at 3/6/12 months, by the EQ-5Q-3L questionnaire) has been met according to the results published in the Rheumatology International
01 Apr 2022 Results assessing the impact of golimumab on health-related quality of life (HRQoL) and other patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) in real-world settings published in the Rheumatology International
13 Nov 2019 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com